diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12418diaendo-12418Research ArticleОбзорыReviewСахарный диабет в условиях вирусной пандемии COVID-19: особенности течения и леченияCourse and treatment of diabetes mellitus in the context of COVID-19https://orcid.org/0000-0003-3893-9972ШестаковаМарина ВладимировнаShestakovaMarina V.

д.м.н., профессор, академик РАН

MD, PhD, Professor

nephro@endocrincentr.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваНаталья ГеоргиевнаMokryshevaNatalya G.

д.м.н., профессор

MD, PhD, Professor

nm70@mail.ruhttps://orcid.org/0000-0002-8175-7886ДедовИван ИвановичDedovIvan I.

д.м.н., профессор, академик РАН

MD, PhD, Professor

dedov@endocrincentr.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology research centreRussian Federation202026062020232132139Copyright © Шестакова М.В., Мокрышева Н.Г., Дедов И.И., 20202020Шестакова М.В., Мокрышева Н.Г., Дедов И.И.Shestakova M.V., Mokrysheva N.G., Dedov I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12418

В 2020 г. мир столкнулся с беспрецедентным вызовом для здоровья людей, связанным со вторжением нового коронавируса SARS COV-2. Это также вызов и для систем здравоохранения всех стран мира. Наиболее уязвимыми в данных условиях оказались пациенты с сахарным диабетом (СД) вследствие особенностей состояния их иммунного статуса и иммунного ответа на вирусную атаку, вследствие чрезмерно высокой активности вируса в условиях гипергликемии, вследствие коморбидности и ожирения, которые часто сопутствуют течению СД. Тяжелое течение заболевания COVID-19 требует обязательного пересмотра привычной сахароснижающей терапии. Крайне важным остается сохранение оптимального контроля гликемии, предупреждение развития кетоацидоза, в связи с чем в большинстве случаев приоритетным препаратом для контроля гликемии становится инсулин. Продолжаются поиски новых препаратов для борьбы с коронавирусной инфекцией, стартуют новые рандомизированные клинические испытания препаратов. В качестве кандидатов на потенциально эффективные средства для борьбы с коронавирусом испытываются в том числе и инновационные антидиабетические средства.

In 2020, the world is facing a historically unparalleled public health challenge associated with the invasion of the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This is also a challenge for the healthcare systems worldwide. Patients with diabetes mellitus (DM) are most vulnerable to COVID-19 because of the peculiarities of their immune response to a virus attack and due to their high susceptibility to viral activity because of hyperglycemia and other comorbid conditions and obesity that often accompany DM. The severity of the COVID-19 disease requires a mandatory review of the usual anti-hyperglycemic therapy. Maintaining optimal glycemic control and preventing the development of ketoacidosis remain extremely important; therefore, insulin becomes the priority drug for glycemic control in most cases. The search for new drugs to fight against the coronavirus infection continues with new randomised clinical drug trials being launched. Innovative anti-diabetic agents are also being tested as candidates for potentially effective anti-coronavirus agents.

коронавирусCOVID-19сахарный диабетангиотензинпревращающий фермент типа 2глюкокортикоидыcoronavirusCOVID-19diabetes mellitustype 2 angiotensin-converting enzymeglucocorticoidsReferencesWorld Health Organization. Coronavirus disease (COVID-2019) situation reports. Avalable from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reportsWorld Health Organization. Coronavirus disease (COVID-2019) situation reports. Avalable from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reportsEpidemiology Working Group for Ncip Epidemic Response. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. (In Chinese)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145−151. doi: https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003Epidemiology Working Group for Ncip Epidemic Response. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. (In Chinese)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145−151. doi: https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003CDC. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 − United States, February 12 − March 28, 2020. MMWR. 2020;69(13):382–386.CDC. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 − United States, February 12 − March 28, 2020. MMWR. 2020;69(13):382–386.Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. doi: https://doi.org/10.1001/jama.2020.4683Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. doi: https://doi.org/10.1001/jama.2020.4683International Diabetes Federation. IDF Diabetes Atlas, 9th dn. Brussels, Belgium; 2019.International Diabetes Federation. IDF Diabetes Atlas, 9th dn. Brussels, Belgium; 2019.Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–310. doi: https://doi.org/10.1016/j.dsx.2020.04.004Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–310. doi: https://doi.org/10.1016/j.dsx.2020.04.004Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395–403. doi: https://doi.org/10.1016/j.dsx.2020.04.018Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395–403. doi: https://doi.org/10.1016/j.dsx.2020.04.018Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: https://doi.org/10.1016/j.cell.2020.02.052.Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: https://doi.org/10.1016/j.cell.2020.02.052.Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi: https://doi.org/10.1038/s41368-020-0074-xXu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi: https://doi.org/10.1038/s41368-020-0074-xZou X, Chen K, Zou J, et al. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection. Front Med. 2020. doi: https://doi.org/10.1007/s11684-020-0754-0Zou X, Chen K, Zou J, et al. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection. Front Med. 2020. doi: https://doi.org/10.1007/s11684-020-0754-0Rabi FA, Al Zoubi MS, Kasasbeh GA, et al. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231–235. doi: https://doi.org/10.3390/pathogens9030231Rabi FA, Al Zoubi MS, Kasasbeh GA, et al. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231–235. doi: https://doi.org/10.3390/pathogens9030231Roca-Ho H, Riera M, Palau V, et al. Characterization of ACE and ACE2 287 expression within different organs of the NOD mouse. Int J Mol Sci. 2017;18(3). pii: E563. doi: https://doi.org/10.3390/ijms18030563Roca-Ho H, Riera M, Palau V, et al. Characterization of ACE and ACE2 287 expression within different organs of the NOD mouse. Int J Mol Sci. 2017;18(3). pii: E563. doi: https://doi.org/10.3390/ijms18030563Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 epidemic. J Medical Virology. 2020. doi: https://doi.org/10.1002/jmv.25887Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 epidemic. J Medical Virology. 2020. doi: https://doi.org/10.1002/jmv.25887Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727−732. doi: https://doi.org/10.1080/22221751.2020.1746199Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727−732. doi: https://doi.org/10.1080/22221751.2020.1746199Wang Q, Fang P, He R, et al. O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci Adv. 2020;6(16):eaaz7086. doi: https://doi.org/10.1126/sciadv.aaz7086Wang Q, Fang P, He R, et al. O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci Adv. 2020;6(16):eaaz7086. doi: https://doi.org/10.1126/sciadv.aaz7086Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;e3319. doi: https://doi.org/10.1002/dmrr.3319Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;e3319. doi: https://doi.org/10.1002/dmrr.3319Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623−628. doi: https://doi.org/10.1111/j.1464-5491.2006.01861.xYang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623−628. doi: https://doi.org/10.1111/j.1464-5491.2006.01861.xBode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;1932296820924469. doi: https://doi.org/10.1177/1932296820924469Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;1932296820924469. doi: https://doi.org/10.1177/1932296820924469Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049−6057. doi: https://doi.org/10.18632/aging.103000Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049−6057. doi: https://doi.org/10.18632/aging.103000Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280−284. doi: https://doi.org/10.1136/pmj.2005.039032Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280−284. doi: https://doi.org/10.1136/pmj.2005.039032Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 − COVID-NET, 14 states, march 1–30, 2020. MMWR Morb Mortal WklyRep. 2020;69(15):458–464. doi: https://doi.org/http://dx.doi.org/10.15585/mmwr.mm6915e3Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 − COVID-NET, 14 states, march 1–30, 2020. MMWR Morb Mortal WklyRep. 2020;69(15):458–464. doi: https://doi.org/http://dx.doi.org/10.15585/mmwr.mm6915e3Hales СМ, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief No. 360, February 2020. Avalable from: https://www.cdc.gov/nchs/data/databriefs/db360-h.pdfHales СМ, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief No. 360, February 2020. Avalable from: https://www.cdc.gov/nchs/data/databriefs/db360-h.pdfSimmonet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020. Avalable from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.22831Simmonet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020. Avalable from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.22831Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19), 6-я версия от 28.04.20 (static-1.rosminzdrav.ru). — Минздрав России, 2020. [Vremennyye metodicheskiye rekomendatsii: profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19), 6-ya versiya ot 28.04.20 (static-1.rosminzdrav.ru). Minzdrav Rossii; 2020. (In Russ.)] Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_%D0%9CR_COVID-19_v6.pdf. Ссылка активна на 28.04.2020.Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19), 6-я версия от 28.04.20 (static-1.rosminzdrav.ru). — Минздрав России, 2020. [Vremennyye metodicheskiye rekomendatsii: profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19), 6-ya versiya ot 28.04.20 (static-1.rosminzdrav.ru). Minzdrav Rossii; 2020. (In Russ.)] Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_%D0%9CR_COVID-19_v6.pdf. Ссылка активна на 28.04.2020.Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020. pii: S2213-8587(20)30152-2. doi: https://doi.org/10.1016/S2213-8587(20)30152-2Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020. pii: S2213-8587(20)30152-2. doi: https://doi.org/10.1016/S2213-8587(20)30152-2Egi M. Acute glycemic control in diabetics. How sweet is optimal? Con: Just as sweet as in nondiabetic is better. J Intensive Care. 2018;6:70. doi: https://doi.org/10.1186/s40560-018-0337-1Egi M. Acute glycemic control in diabetics. How sweet is optimal? Con: Just as sweet as in nondiabetic is better. J Intensive Care. 2018;6:70. doi: https://doi.org/10.1186/s40560-018-0337-1Mendy A, Gopal R, Alcorn JF, Forno E. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology. 2019;24(7):646−651. doi: https://doi.org/10.1111/resp.13486Mendy A, Gopal R, Alcorn JF, Forno E. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology. 2019;24(7):646−651. doi: https://doi.org/10.1111/resp.13486Ho T, Huang C, Tsai Y, et al. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res. 2019;20(1):69. doi: https://doi.org/10.1186/s12931-019-1035-9Ho T, Huang C, Tsai Y, et al. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res. 2019;20(1):69. doi: https://doi.org/10.1186/s12931-019-1035-9Мокрышева Н.Г., Галстян Г.Р., Киржаков М.А., и др. Рекомендации для врачей по лечению эндокринных заболеваний в условиях пандемии COVID-19. Пандемия COVID-19 и эндокринопатии. — М.: ФГБУ «НМИЦ эндокринологии», 2020. [Mokrysheva NG, Galstyan GR, Kirzhakov MA, et al. Rekomendatsii dlya vrachey po lecheniyu endokrinnykh zabolevaniy v usloviyakh pandemii COVID-19. Pandemiya COVID-19 i endokrinopatii. Moscow: FGBU «NMITS endokrinologii»; 2020. (In Russ.)] Доступно по: https://www.endocrincentr.ru/rekomendacii-dlya-vrachey-po-lecheniyu-endokrinnyh-zabolevaniy-v-usloviyah. Ссылка активна на 28.04.2020.Мокрышева Н.Г., Галстян Г.Р., Киржаков М.А., и др. Рекомендации для врачей по лечению эндокринных заболеваний в условиях пандемии COVID-19. Пандемия COVID-19 и эндокринопатии. — М.: ФГБУ «НМИЦ эндокринологии», 2020. [Mokrysheva NG, Galstyan GR, Kirzhakov MA, et al. Rekomendatsii dlya vrachey po lecheniyu endokrinnykh zabolevaniy v usloviyakh pandemii COVID-19. Pandemiya COVID-19 i endokrinopatii. Moscow: FGBU «NMITS endokrinologii»; 2020. (In Russ.)] Доступно по: https://www.endocrincentr.ru/rekomendacii-dlya-vrachey-po-lecheniyu-endokrinnyh-zabolevaniy-v-usloviyah. Ссылка активна на 28.04.2020.Гринева Е.Н., Халимов Ю.Ш., Бабенко А.Ю., и др. Рекомендации по ведению больных COVID-19 и эндокринными заболеваниями в период пандемии. — М.: ФГБУ «НМИЦ им. В.А. Алмазова», 2020. [Grineva EN, KHalimov YuSh, Babenko AYu, et al. Rekomendatsii po vedeniyu bol’nykh COVID-19 i endokrinnymi zabolevaniyami v period pandemii. Moscow: FGBU «NMITS im. V.A. Almazova»; 2020. (In Russ.)] Доступно по: http://www.almazovcentre.ru/?p=62944. Ссылка активна на 28.04.2020.Гринева Е.Н., Халимов Ю.Ш., Бабенко А.Ю., и др. Рекомендации по ведению больных COVID-19 и эндокринными заболеваниями в период пандемии. — М.: ФГБУ «НМИЦ им. В.А. Алмазова», 2020. [Grineva EN, KHalimov YuSh, Babenko AYu, et al. Rekomendatsii po vedeniyu bol’nykh COVID-19 i endokrinnymi zabolevaniyami v period pandemii. Moscow: FGBU «NMITS im. V.A. Almazova»; 2020. (In Russ.)] Доступно по: http://www.almazovcentre.ru/?p=62944. Ссылка активна на 28.04.2020.Royal Australian College of General Practitioners (RACGP). Diabetes management during the coronavirus pandemic: be proactive and prepared. Avalable from: https://www.racgp.org.au/getmedia/97a5abb4-1290-42cb-91c0-eabcaa8ca590/Diabetes-management-during-coronavirus-pandemic_1.pdf.aspxRoyal Australian College of General Practitioners (RACGP). Diabetes management during the coronavirus pandemic: be proactive and prepared. Avalable from: https://www.racgp.org.au/getmedia/97a5abb4-1290-42cb-91c0-eabcaa8ca590/Diabetes-management-during-coronavirus-pandemic_1.pdf.aspxHartmann-Boyce J, Morris E, Goyder C, et al. Managing diabetes during the COVID-19 pandemic. [cited 8 April 2020] Avalable from: https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/Hartmann-Boyce J, Morris E, Goyder C, et al. Managing diabetes during the COVID-19 pandemic. [cited 8 April 2020] Avalable from: https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/Christiansen C, Johansen M, Christensen S, et al. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit Care. 2013;17(5):R192. doi: https://doi.org/10.1186/cc12886Christiansen C, Johansen M, Christensen S, et al. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit Care. 2013;17(5):R192. doi: https://doi.org/10.1186/cc12886Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19). [cited 17 April 2020] Avalable from: https://clinicaltrials.gov/ct2/show/NCT04350593Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19). [cited 17 April 2020] Avalable from: https://clinicaltrials.gov/ct2/show/NCT04350593Wiviott SD, Raz I, Bonaca MP, et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347−357. doi: https://doi.org/10.1056/NEJMoa1812389Wiviott SD, Raz I, Bonaca MP, et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347−357. doi: https://doi.org/10.1056/NEJMoa1812389McMurray JJ, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995−2008. doi: https://doi.org/10.1056/NEJMoa1911303McMurray JJ, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995−2008. doi: https://doi.org/10.1056/NEJMoa1911303Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып. // Сахарный диабет. — 2019. — Т. 22. — №S1-1. — C. 1–144. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(S1-1):1–144. (In Russ.)] doi: https://doi.org/10.14341/DM221S1Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып. // Сахарный диабет. — 2019. — Т. 22. — №S1-1. — C. 1–144. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(S1-1):1–144. (In Russ.)] doi: https://doi.org/10.14341/DM221S1Petrillo MG, Bortner C, Cidlowski JA. Glucocorticoids: inflammation and immunity. The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease.2017;43−63. doi: https://doi.org/10.1007/978-3-319-45950-9_3Petrillo MG, Bortner C, Cidlowski JA. Glucocorticoids: inflammation and immunity. The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease.2017;43−63. doi: https://doi.org/10.1007/978-3-319-45950-9_3Russell B, Moss C, Rigg A, Hemelrijck MV. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancer. 2020;14:1023. doi: https://doi.org/10.3332/ecancer.2020.1023Russell B, Moss C, Rigg A, Hemelrijck MV. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancer. 2020;14:1023. doi: https://doi.org/10.3332/ecancer.2020.1023Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52(Pt 8):715–720. https://doi.org/10.1099/jmm.0.05320-0Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52(Pt 8):715–720. https://doi.org/10.1099/jmm.0.05320-0Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. (In Chinese)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E004. https://doi.org/10.3760/cma.j.cn112148-20200220-00105Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. (In Chinese)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E004. https://doi.org/10.3760/cma.j.cn112148-20200220-00105European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. [cited 13 March 2020] Avalable from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-angEuropean Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. [cited 13 March 2020] Avalable from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-angАmerican Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. [cited 20 March 2020] Avalable from: https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jspАmerican Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. [cited 20 March 2020] Avalable from: https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp

The authors declare that there are no conflicts of interest present.